We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Add DaVita (DVA) to Your Portfolio Now
Read MoreHide Full Article
DaVita Inc. (DVA - Free Report) is likely to gain from the promising fourth-quarter 2019 results and a raised guidance for 2020.
In a year’s time, shares of DaVita have rallied 45.5% compared with the industry's 13.5% rise. Meanwhile, the S&P 500 Index has rallied 21%.
With a market capitalization of $11.02 billion, DaVita is a leading provider of dialysis services in the United States to patients suffering from chronic kidney failure. The company’s earnings are anticipated to grow 20.4% over the next five years. The company’s trailing four-quarter positive earnings surprise is 10.8%, on average.
Let’s delve deeper into the factors that substantiate DaVita’s Zacks Rank #1 (Strong Buy) at present.
Factors Driving DaVita
DaVita reported fourth-quarter 2019 adjusted earnings per share (EPS) of $1.86, which shows a massive surge from the year-ago quarter’s 90 cents.
Total revenues in the quarter rose 2.7% year over year to $2.90 billion.
Notably, the company performed impressively in the United States and abroad.
Total U.S. dialysis treatments in the fourth quarter were 7,681,462, or an average of 96,744 treatments per day, up 1.7% year over year.
Also, the company provided dialysis services to around 235,500 patients at 3,012 outpatient dialysis centers, of which 2,753 centers were located in the United States and 259 centers in 10 countries outside the United States.
Resultantly, in the fourth quarter, net dialysis and related lab patient service revenues totaled $2.77 billion, up 1.8% on a year-over-year basis.
AmerisourceBergen’s long-term earnings are expected to grow 7.4%.
Cardinal Health’s long-term earnings are projected to rise 6.2%.
Patterson long-term earnings are estimated to climb 6.4%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Here's Why You Should Add DaVita (DVA) to Your Portfolio Now
DaVita Inc. (DVA - Free Report) is likely to gain from the promising fourth-quarter 2019 results and a raised guidance for 2020.
In a year’s time, shares of DaVita have rallied 45.5% compared with the industry's 13.5% rise. Meanwhile, the S&P 500 Index has rallied 21%.
With a market capitalization of $11.02 billion, DaVita is a leading provider of dialysis services in the United States to patients suffering from chronic kidney failure. The company’s earnings are anticipated to grow 20.4% over the next five years. The company’s trailing four-quarter positive earnings surprise is 10.8%, on average.
Let’s delve deeper into the factors that substantiate DaVita’s Zacks Rank #1 (Strong Buy) at present.
Factors Driving DaVita
DaVita reported fourth-quarter 2019 adjusted earnings per share (EPS) of $1.86, which shows a massive surge from the year-ago quarter’s 90 cents.
Total revenues in the quarter rose 2.7% year over year to $2.90 billion.
Notably, the company performed impressively in the United States and abroad.
Total U.S. dialysis treatments in the fourth quarter were 7,681,462, or an average of 96,744 treatments per day, up 1.7% year over year.
Also, the company provided dialysis services to around 235,500 patients at 3,012 outpatient dialysis centers, of which 2,753 centers were located in the United States and 259 centers in 10 countries outside the United States.
Resultantly, in the fourth quarter, net dialysis and related lab patient service revenues totaled $2.77 billion, up 1.8% on a year-over-year basis.
DaVita Inc. Price and Consensus
DaVita Inc. price-consensus-chart | DaVita Inc. Quote
Reflective of these, DaVita issued a strong guidance for 2020.
The company now expects adjusted EPS between $5.75 and $6.25. This compares to the earlier projected band of $5.25-$5.75.
The company also expects 2020 revenues between $11.50 billion and $11.70 billion.
Which Way Are Estimates Headed?
For 2020, the Zacks Consensus Estimate for revenues is pegged at $11.61 billion. For adjusted EPS, the same stands at $6.06.
Other Key Picks
Other top-ranked stocks in the broader medical space are AmerisourceBergen Corporation , Cardinal Health (CAH - Free Report) and Patterson Companies (PDCO - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here..
AmerisourceBergen’s long-term earnings are expected to grow 7.4%.
Cardinal Health’s long-term earnings are projected to rise 6.2%.
Patterson long-term earnings are estimated to climb 6.4%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>